中国普外基础与临床杂志

中国普外基础与临床杂志

原发性肝癌的综合治疗

查看全文

关键词: 原发性肝癌; 综合治疗; 分期

引用本文: 戴朝六, 赵阳. 原发性肝癌的综合治疗. 中国普外基础与临床杂志, 2014, 21(2): 133-137. doi: 10.7507/1007-9424.20140031 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Jemal A, Bray F, Center MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61(2):69-90.
2. 郝捷, 陈万青.中国肿瘤登记年报(2012)[M].北京:军事医学科学出版社, 2012.
3. Okuda K, Ohtsuki T, Obata H, et al.Natural history of hepatocellular carcinoma and prognosis in relation to treatment.Study of 850 patients[J].Cancer, 1985, 56(4):918-928.
4. Llovet JM, Bruix J.Prospective validation of the Cancer of the Liver Italian Program (CLIP) score:a new prognostic system for patients with cirrhosis and hepatocellular carcinoma[J].Hepatology, 2000, 32(3):679-680.
5. Llovet JM, Brú C, Bruix J.Prognosis of hepatocellular carcinoma:the BCLC staging classification[J].Semin Liver Dis, 1999, 19(3):329-338.
6. Edge SB, Compton CC, Fritz AG, et al.AJCC cancer staging manual[M].7th ed.New York, NY:Springer, 2010:237-246.
7. Leung TW, Tang AM, Zee B, et al.Construction of the Chinese university prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the cancer of the liver Italian program staging system:a study based on 926 patients[J].Cancer, 2002, 94(6):1760-1769.
8. Tateishi R, Yoshida H, Shiina S, et al.Proposal of a new prognostic model for hepatocellular carcinoma:an analysis of 403 patients[J].Gut, 2005, 54(3):419-425.
9. Kudo M, Chung H, Osaki Y.Prognostic staging system for hepa-tocellular carcinoma (CLIP score):its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)[J].J Gastroenterol, 2003, 38(3):207-215.
10. 中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].肝脏, 2004, 9(S1):67-68.
11. 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志, 2011, 16(11):1141-1159.
12. Nanashima A, Tobinaga S, Masuda J, et al.Selecting treatment for hepatocellular carcinoma based on the results of hepatic resection and local ablation therapy[J].J Surg Oncol, 2010, 101(6):481-485.
13. Hung HH, Chiou YY, Hsia CY, et al.Survival rates are comp-arable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas[J].Clin Gastroenterol Hepatol, 2011, 9(1):79-86.
14. 许秋然, 郑鑫, 姚英民, 等.肝移植术与肝切除术治疗原发性肝癌的meta分析[J].西安交通大学学报:医学版, 2012, 33(5):576-582.
15. Kudo M, Han KH, Kokudo N, et al.Liver cancer working group report[J].Jpn J Clin Oncol, 2010, 40(Suppl 1):i19-i27.
16. Chen XP, Qiu FZ, Wu ZD, et al.Hepatectomy for huge hepatocellular carcinoma in 634 cases[J].World J Gastroenterol, 2006, 12(29):4652-4655.
17. Llovet JM, Real MI, Montaña X, et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet, 2002, 359(9319):1734-1739.
18. Vitale A, Saracino E, Boccagni P, et al.Validation of the BCLC prognostic system in surgical hepatocellular cancer patients[J].Transplant Proc, 2009, 41(4):1260-1263.
19. Inoue K, Nakamura T, Kinoshita T, et al.Volume reduction surgery for advanced hepatocellular carcinoma[J].J Cancer Res Clin Oncol, 2004, 130(6):362-366.
20. 韩国宏, 白苇, 梁洁, 等.TACE联合索拉非尼治疗中晚期肝细胞肝癌的初步观察[J].临床肿瘤学杂志, 2009, 14(5):401-404.
21. Hsu C, Morita S, Hu FC, et al.Perspectives on the design of clinical trials combining transarterial chemoembolization and mole-cular targeted therapy[J].Liver Cancer, 2012, 1(3/4):168-176.
22. Qin S, Bai Y, Lim HY, et al.Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxo-rubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol, 2013, 31(28):3501-3508.
23. 田浩, 程朝辉, 张瑞刚, 等.FOLFOX4方案治疗中晚期肝癌的临床疗效[J].肿瘤基础与临床, 2011, 24(6):495-496.
24. 黄苹, 陈强, 张其忠, 等.亚砷酸注射液治疗中晚期原发性肝癌的临床研究[J].中国误诊学杂志, 2002, 2(11):1642-1643.
25. 屈凤莲, 郝学志, 秦叔逵, 等.亚砷酸注射液治疗原发性肝癌的Ⅱ期多中心临床研究[J].中华肿瘤杂志, 2011, 33(9):697-701.